Our pipeline is focused on research in therapeutic areas where we believe we have an opportunity to deliver transformational medicines to patients. The safety and efficacy of the agents and/or uses under investigation Immunology Pipeline have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Information as of February 2021.

Compound Research Area Phase 1 Phase 2 Phase 3

abatacept Idiopathic Inflammatory Myopathy

belatacept Switch from Calcineurin Inhibitor Renal Transplant

ozanimod Ulcerative Colitis

Crohn’s Disease

deucravacitinib Psoriasis

Psoriatic Arthritis

Lupus Nephritis

Systemic Lupus Erythematosus

Crohn’s Disease

Ulcerative Colitis

iberdomide Systemic Lupus Erythematosus

cendakimab Eosinophilic Esophagitis

branebrutinib Rheumatoid Arthritis

Systemic Lupus Erythematosus

Sjögren’s Syndrome

TYK2 Inhibitor Autoimmune Disease

TLR 7/8 Inhibitor Autoimmune Disease

S1PR1 Modulator Autoimmune Disease

IL-2 Mutein Autoimmune Disease

MK2 Inhibitor Autoimmune Disease

IL2-CD25 Autoimmune Disease

Anti-CD40 Autoimmune Disease

TYK2 Inhibitor ♦ (Nimbus) Autoimmune Disease

Immune Tolerance ♦ (Anokion) Multiple Sclerosis

♦ Development Partnership: TYK2 Inhibitor (Nimbus): Nimbus Therapeutics; Immune Tolerance: Anokion Phase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects. Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study. Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.

IMM-US-2100272 03/21